These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14989491)

  • 1. Correlations of breast carcinoma biomarkers and p53 tested by FASAY and immunohistochemistry.
    Vagunda V; Smardová J; Vagundová M; Jandáková E; Zaloudík J; Koukalová H
    Pathol Res Pract; 2003; 199(12):795-801. PubMed ID: 14989491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
    Lee WY; Jin YT; Tzeng CC
    Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry.
    Smardová J; Vagunda V; Jandáková E; Vagundová M; Koukalová H; Kovarík J; Zaloudík J
    Neoplasma; 1999; 46(6):384-9. PubMed ID: 10732868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
    Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
    J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
    Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
    Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
    Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressions of cyclin D1, p53, bcl-2, and bax in infiltrative ductal carcinoma of the breast: correlations with clinicopathologic characteristics.
    Arýkök AT; Onal BU; Han U
    Breast J; 2006; 12(4):391-2. PubMed ID: 16848860
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlations in survivin expression with the expression of p53 and bcl-2 in invasive ductal carcinoma of the breast.
    Al-Joudi FS; Iskandar ZA; Imran AK
    Southeast Asian J Trop Med Public Health; 2007 Sep; 38(5):904-10. PubMed ID: 18041310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, BCL-2, hormone receptors and tumor proliferation.
    Pillai MR; Kesari AL; Chellam VG; Madhavan J; Nair P; Nair MK
    Pathol Res Pract; 1998; 194(8):549-57. PubMed ID: 9779489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients.
    Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G
    Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
    Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
    Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different proliferative patterns characterize different preinvasive breast lesions.
    Viacava P; Naccarato AG; Bevilacqua G
    J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Flow cytometry-pathology combined study of breast cancer].
    Yu ZY; Yu JM; Wu TH; Zhuo PY; Wang SF; Li M; Zhang X; Lü BY; Liu YB
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):420-2. PubMed ID: 16188128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.